Humacyte, Inc.
Business
Humacyte, Inc. is a commercial-stage biotechnology company developing bioengineered human tissues for implantation. The company commercializes Symvess, an acellular tissue engineered vessel approved by the FDA in December 2024 for extremity arterial injury repair. Its pipeline includes applications in hemodialysis access, peripheral artery disease, coronary bypass grafting, and emerging indications such as pancreatic islet delivery and engineered organs. Humacyte sells directly in the United States and has granted Fresenius Medical Care exclusive distribution rights outside the U.S. and EU.
Summary from 10-K filed 2026-03-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 2 | 0 | — | — | — | |
| Cost of goods sold | 10 | 0 | — | — | — | |
| Research and development | 69 | 89 | 77 | 63 | 61 | |
| General and administrative | 31 | 26 | 23 | 23 | 21 | |
| Total operating expenses | 110 | 114 | — | — | — | |
| Loss from operations | −108 | −114 | −100 | −85 | −81 | |
| Interest income | 3 | 4 | 5 | 3 | 16,000 | |
| Change in fair value of Contingent Earnout Liability | 59 | −33 | −10 | 76 | 56 | |
| Interest expense | −11 | −9 | −7 | — | — | |
| Change in fair value of derivatives | 39 | 4 | −260,000 | 417,000 | — | |
| Loss on extinguishment of debt | −22 | 0 | −2 | 0 | 3 | |
| Total other expense, net | 67 | −34 | −11 | 73 | 55 | |
| Net loss and comprehensive loss | −41 | −149 | −111 | −12 | −26 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −0.26 | −1.26 | −1.07 | −0.12 | −0.66 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −0.26 | −1.26 | −1.07 | −0.12 | −0.66 | |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158 | 118 | 103 | 103 | 40 | |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158 | 118 | 103 | 103 | 40 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 51 | 45 | 80 | 150 | 218 | |
| Inventory, net | 14 | 0 | — | — | — | |
| Accounts receivable | 441,000 | 0 | 0 | 31,000 | 176,000 | |
| Prepaid expenses and other current assets | 3 | 3 | 3 | 2 | 4 | |
| Total current assets | 68 | 48 | 83 | 154 | 229 | |
| Restricted cash | 209,000 | 50 | 209,000 | — | — | |
| Property and equipment, net | 19 | 23 | 27 | 30 | 35 | |
| Finance lease right-of-use assets, net | 29 | 16 | 17 | 19 | 21 | |
| Other long-term assets | 672,000 | 1 | 632,000 | 682,000 | — | |
| Total assets | 116 | 138 | 128 | 204 | 287 | |
| Accounts payable | 5 | 4 | 6 | 2 | 2 | |
| Accrued expenses | 11 | 11 | 9 | 7 | 7 | |
| Finance lease obligation, current portion | 2 | 3 | 3 | 2 | 2 | |
| Revenue interest liability, current portion | 0 | 885,000 | — | — | — | |
| Other current liabilities | 0 | 238,000 | 53,000 | — | — | |
| Total current liabilities | 18 | 20 | 18 | 20 | 11 | |
| Long-term debt | 35 | 0 | — | — | — | |
| Contingent Earnout Liability | 11 | 71 | 38 | 28 | 104 | |
| Revenue interest liability | 0 | 63 | — | — | — | |
| Common stock warrant liabilities | 19 | 19 | 78,000 | 80,000 | 497,000 | |
| Finance lease obligation, net of current portion | 27 | 14 | 16 | 19 | 21 | |
| Contingent derivative liability | 0 | 2 | 3 | 0 | — | |
| Other long-term liabilities | 2 | 983,000 | 711,000 | 712,000 | — | |
| Total liabilities | 113 | 191 | 115 | 87 | 164 | |
| Preferred stock, $0.0001 par value; 20,000,000 shares designated as of December 31, 2025 and 2024, 0 shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 350,000,000 and 250,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 193,000,611 and 130,027,509 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 20,000 | 13,000 | 10,000 | 10,000 | 10,000 | |
| Additional paid-in capital | 730 | 633 | 551 | 543 | 537 | |
| Accumulated deficit | −727 | −686 | −537 | −427 | −415 | |
| Total stockholders equity (deficit) | 3 | −53 | 14 | 117 | 122 | |
| Total liabilities and stockholders equity (deficit) | 116 | 138 | 128 | 204 | 287 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 5 | 5 | 6 | 6 | 6 | |
| Stock-based compensation expense | 10 | 6 | 7 | 6 | 10 | |
| Non-cash interest expense | 9 | 8 | 3 | 0 | — | |
| Loss on disposal of property and equipment | 5,000 | 4,000 | 18,000 | 6,000 | 0 | |
| Inventory reserve | 9 | 0 | — | — | — | |
| Amortization expense | 2 | 2 | 2 | 2 | 2 | |
| Non-cash operating lease costs | 44,000 | 53,000 | 50,000 | 45,000 | 42,000 | |
| Accounts receivable | −261,000 | 0 | 31,000 | 145,000 | −63,000 | |
| Inventory | −22 | 0 | — | — | — | |
| Prepaid expenses and other current assets | −527,000 | 88,000 | −388,000 | 1 | −2 | |
| Accounts payable | 973,000 | −2 | 5 | −509,000 | −197,000 | |
| Accrued expenses | −2 | 2 | 2 | 247,000 | 2 | |
| Operating lease obligation | −44,000 | −53,000 | −50,000 | −45,000 | −42,000 | |
| Net cash used in operating activities | −105 | −98 | −73 | −71 | −81 | |
| Purchase of property and equipment, net | −884,000 | −2 | −2 | −1 | −220,000 | |
| Net cash used in investing activities | −884,000 | −2 | −173,000 | 5 | −8 | |
| Proceeds from the Term Loan Facility | 40 | 0 | — | — | — | |
| Payments of transaction costs related to the Loan Agreement | −774,000 | 0 | −1 | — | — | |
| Payments of costs related to public offering | −340,000 | −350,000 | 0 | — | — | |
| Payments on revenue interest liability | −45,000 | 0 | — | — | — | |
| Settlement of the Purchase Agreement | −88 | 0 | — | — | — | |
| Proceeds from the Purchase Agreement, net of issuance costs | 0 | 20 | 39 | 0 | — | |
| Payments of transaction costs related to the Purchase Agreement | 0 | −500,000 | −1 | 0 | — | |
| Proceeds from the exercise of stock options | 61,000 | 2 | 566,000 | 535,000 | 598,000 | |
| Proceeds from the JDRF Agreement | 175,000 | 240,000 | 80,000 | 0 | — | |
| Payments of finance lease principal | −3 | −3 | −2 | −2 | −2 | |
| Net cash provided by financing activities | 61 | 114 | 5 | −1 | 267 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −44 | 14 | −69 | −68 | 178 | |
| Unpaid transaction costs related to the Loan Agreement | 446,000 | 0 | — | — | — | |
| Increase in right-of-use assets and lease liabilities resulting from lease remeasurement | 15 | 0 | — | — | — | |
| Accrual of transaction costs associated with public offering | 156,000 | 0 | — | — | — | |
| Debt discount from embedded contingent derivative liability | 0 | 2 | 2 | — | — | |
| Issuance of commitment shares pursuant to the Common Stock Purchase Agreement | 0 | 708,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Humacyte, Inc.'s CIK number?
Humacyte, Inc.'s SEC CIK number is 0001818382 (1818382). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Humacyte, Inc.'s SEC filings?
All of Humacyte, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Humacyte, Inc. last report earnings?
Humacyte, Inc. (HUMA) most recently filed an earnings 8-K with the SEC on Mar 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-031780). This is Humacyte, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Humacyte, Inc.'s most recent earnings 8-K?
Humacyte, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 19, 2026 under accession 0001104659-26-031780. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Humacyte, Inc.'s latest earnings 8-K →
Look up any company's CIK number →